CoChat

Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2

Open access
Zhang, Qi, Ju, Bin, Ge, Jiwan, Chan, Jasper Fuk-Woo, Cheng, Lin, Wang, Ruoke, Huang, Weijin, Fang, Mengqi, Chen, Peng, Zhou, Bing, Song, Shuo, Shan, Sisi, Yan, Baohua, Zhang, Senyan, Ge, Xiangyang, Yu, Jiazhen, Zhao, Juanjuan, Wang, Haiyan, Liu, Li, Lv, Qining, Fu, Lili, Shi, Xuanling, Yuen, Kwok Yung, Liu, Lei, Wang, Youchun, Chen, Zhiwei, Zhang, Linqi, Wang, Xinquan, Zhang, Zheng · 2021 · Nature Communications
Cited by 125

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Abstract

Neutralizing antibodies (nAbs) to SARS-CoV-2 hold powerful potentials for clinical interventions against COVID-19 disease. However, their common genetic and biologic features remain elusive. Here we interrogate a total of 165 antibodies from eight COVID-19 patients, and find that potent nAbs from different patients have disproportionally high representation of IGHV3-53/3-66 usage, and therefore termed as public antibodies. Crystal structural comparison of these antibodies reveals they share similar angle of approach to RBD, overlap in buried surface and binding residues on RBD, and have substantial spatial clash with receptor angiotensin-converting enzyme-2 (ACE2) in binding to RBD. Site-directed mutagenesis confirms these common binding features although some minor differences are found. One representative antibody, P5A-3C8, demonstrates extraordinarily protective efficacy in a golden Syrian hamster model against SARS-CoV-2 infection. However, virus escape analysis identifies a single natural mutation in RBD, namely K417N found in B.1.351 variant from South Africa, abolished the neutralizing activity of these public antibodies. The discovery of public antibodies and shared escape mutation highlight the intricate relationship between antibody response and SARS-CoV-2, and provide critical reference for the development of antibody and vaccine strategies to overcome the antigenic variation of SARS-CoV-2.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-021-24514-w

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Cited by

See all 125

Metadata

Authors
Zhang, Q., Ju, B., Ge, J., Chan, J. F.-W., Cheng, L., Wang, R., Huang, W., Fang, M., Chen, P., Zhou, B., Song, S., Shan, S., Yan, B., Zhang, S., Ge, X., Yu, J., Zhao, J., Wang, H., Liu, L., Lv, Q., Fu, L., Shi, X., Yuen, K. Y., Liu, L., Wang, Y., Chen, Z., Zhang, L., Wang, X., & Zhang, Z.
Venue
Nature Communications
Published
2021-07-09
Volume
12
Issue
1
Pages
4210-4210
ISSN
2041-1723 (ISSN-L)
OpenAlex
W3182696180
Cited by
125
References
29
FWCI
7.18
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2. https://app.cochat.ai/papers/10.1038/s41467-021-24514-w
The paper
Zhang, Q., Ju, B., Ge, J., Chan, J. F.-W., Cheng, L., Wang, R., Huang, W., Fang, M., Chen, P., Zhou, B., Song, S., Shan, S., Yan, B., Zhang, S., Ge, X., Yu, J., Zhao, J., Wang, H., Liu, L., . . . Zhang, Z. (2021). Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2. Nature Communications. https://doi.org/10.1038/s41467-021-24514-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.